Abcuro is a clinical-stage biotechnology company developing first-in-class immunotherapies for autoimmune diseases and cancer through precise modulation of effector cytotoxic T and NK cells. These cells can be specifically targeted as they express the receptor KLRG1 (killer cell lectin-like receptor G1).
In certain autoimmune diseases, KLRG1-expressing T cells are a major source of chronic tissue damage. In oncology, tumor cells that express E- or N- cadherin inhibit the anti-tumor activity of T and NK cells because E- and N-cadherin bind to KLRG1, and KLRG1 functions as an immune checkpoint inhibitory receptor.
KLRG1 was identified as a compelling clinical therapeutic target through Abcuro’s bioinformatic analyses of clinical databases, as well as patient tissue and pathological immune cell transcriptome analyses.